Keyvantage Wealth LLC Trims Holdings in Eli Lilly and Company $LLY

Keyvantage Wealth LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 13.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 537 shares of the company’s stock after selling 82 shares during the period. Keyvantage Wealth LLC’s holdings in Eli Lilly and Company were worth $418,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. increased its position in Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Eli Lilly and Company by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after buying an additional 81,587 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after buying an additional 682,203 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $4,613,912,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,024.67 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,033.62. The company has a fifty day simple moving average of $826.89 and a two-hundred day simple moving average of $780.87. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market cap of $968.70 billion, a price-to-earnings ratio of 66.97, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the previous year, the firm posted $1.18 EPS. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research note on Friday, October 10th. BMO Capital Markets increased their price target on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Leerink Partners upgraded shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $886.00 to $1,104.00 in a report on Monday, November 10th. Finally, Morgan Stanley increased their target price on shares of Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the stock an “overweight” rating in a research note on Thursday. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $999.28.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.